Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

NCT04078152 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04078152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04078152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
September 5, 2019
Completion date
October 31, 2024
Enrollment
163 (actual)
Sites
116

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor